Skip to content
lifestyle.hubspotes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Molecular Partners
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
August 25, 2026
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
July 16, 2026
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
July 15, 2026
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
July 6, 2026
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
July 2, 2026
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
May 12, 2026
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
May 4, 2026
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
May 1, 2026
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
April 19, 2026
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
April 14, 2026
1
2
Next Page
→